Biotech News

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

Cullinan Therapeutics, Inc. (CGEM)Cullinan Therapeutics, Inc.Company update

Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that members of its management team will participate in fireside chats at the following upcoming investor conferences:

Related news

Cullinan Therapeutics, Inc.

Autoimmune and Oncology Therapeutics Cullinan Therapeutics develops targeted therapies and immune-cell engagers across autoimmune disease and cancer. CLN-978 CLN-978 is a compact CD19-directed T-cell engager designed to deplete B cells. It is being studied in systemic lupus erythematosus and rheumatoid arthritis, including multi-dose...

Recent company news

Stock data

Close
9.07 USD
Market cap
942.77M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States